newsfilter
← Latest News
GlobeNewswire·

Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile

Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control The Company is developing Teverelix® as a first in class market product for Acute